3 clinics shown
Mental health services are provided at East Al Mental Health in Opelika, located on County Road 148. The practice offers outpatient psychiatric care for adults and adolescents in the East Alabama region. Specific treatment modalities such as TMS, ketamine, or esketamine are not detailed in available information; prospective patients should contact the clinic to confirm which services and therapeutic approaches are offered.
East Alabama Medical Center operates a general medical facility on Pepperell Parkway in Opelika, serving patients across Lee County and surrounding areas. The center is categorized as a full-service medical facility rather than a specialized psychiatric or TMS clinic. Patients seeking treatment-resistant depression care, TMS therapy, esketamine, or ketamine treatments should contact the facility directly to confirm whether these services are available through its psychiatry or behavioral health departments.
East Alabama Mental Health operates a community mental health center on Center Hill Drive in Opelika, serving children and adults with psychiatric and psychological needs. The facility provides outpatient mental health services including evaluations, therapy, and medication management. Child psychology services are available as part of the center's broader behavioral health programming. Specific procedural treatments such as TMS or esketamine are not detailed in available information.
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.